At BIOLIFE4D, we plan to bring revolutionary life-saving care to the masses, and you now have an opportunity to be a part of this revolution by joining our team and becoming a shareholder.
An investment in BIOLIFE4D is not a donation, but rather an equity investment in the company’s goal of bettering humanity’s future. When you become a shareholder by purchasing stock, you will be directly contributing towards our efforts to bring this life-saving technology to the market.
You can join investors from across the world whose support has already enabled our team to make significant advancements towards bioengineering a human heart viable for transplantation using a patient’s own cells.
And to make an equity investment, all you have to do is contact our Investor Relations Team at 1 (224) 602-9569 and they will be happy to assist.
Investing in Mankind
Heart disease doesn’t discriminate. It is the leading cause of death for both men and women. Globally! In fact, cardiovascular disease surpasses the annual mortality rate of all types of cancer combined. In the U.S. alone, one person dies of a heart disease-related event every minute. And in China, cardiovascular disease claims a life every 10 seconds. This is a truly world-wide problem.
As a matter of fact, cardiovascular disease is currently the cause of one in every three deaths in every developed nation throughout the world. In the U.S. alone, heart disease claims more than 610,000 lives every year. One major reason – a shortage of supply of viable donor hearts for transplant. This lack of supply means that only about 3,500 heart transplants take place each year in the U.S. and only about 1,500 additional heart transplants take place outside of the US each year. Given that there are an estimated 7.5 billion people currently alive around the world, that’s a staggering amount of people who will die because they won’t have access to a donor heart transplant that could save their life.
And while a donor heart transplant could save your life, it is in reality essentially only trading one disease for another. Because of the massive immunosuppressant therapy required to prevent rejection of the donor organ the patient is susceptible to all sorts of infections and diseases, and a donor heart only lasts about 10 years on average.
BIOLIFE4D is working hard to address this critical unmet need in the treatment of this devastating disease. The innovative technology we are working on specifically addresses these challenges. By bioengineering an actual human heart made out of the patient’s own cells we are not only addressing the tremendous supply issue but simultaneously eliminating the need for the extensive immunosuppressant therapy. Not only would the patient’s life be saved, but they could potentially enjoy a good quality of life. This will be our gift, the gift of time.
We have a truly incredible team of doctors and scientists assembled, all with the goal of pushing this incredible technology to the market to save lives. And with backgrounds from MIT, Harvard, Johns Hopkins, Carnegie Mellon, University of Virginia, Northwestern University, University of Texas, Technion, and many others we believe we will be able to accomplish this as expeditiously as possible.
As a result of the incredible progress we have already been able to achieve we have received extensive coverage in the media. We have been on the cover of Crain’s Chicago Business, featured in USA today, yahoo finance, fast company, readers digest, BBC, MSN and the list goes on. You can see many of them on the media page of our website, and you can also see an exciting new Press Release here.
Why invest? As BIOLIFE4D succeeds, so too should its investors! After all, without all of the incredible support we continue to enjoy from our equity shareholders we would not have been able to accomplish so much so quickly. With a projected market in the billions of dollars, bioengineering human hearts can be medicine’s next big frontier. And if that wasn’t enough, while we are currently focused on the heart this technology could also potentially be leveraged to address numerous other medical challenges, such as livers and kidneys.
For a limited time you now have the ability to invest in this incredible new technology before it goes mainstream and potentially revolutionizes the healthcare industry. This is your opportunity to get in on the ground floor and own equity in BIOLIFE4D.
Contact Investor Relations:
If you have any questions, please give our Investor Relations Team a call at 1 (224) 602-9569, or if you prefer just fill out the information below and a member of our team will reach back out to you:
Investing is Easy:
You can invest now! Just give our Investor Relations Team a call at 1 (224) 602-9569 and we will help you through the quick and easy process. It only takes a few minutes, and payment can be made via ACH, e-check, Debit Card or Credit Card.
Amount of Raise: $50 Million | Price Per Share: $12.00 | Minimum Investment: $1,080